期刊
JOURNAL OF CLINICAL MEDICINE
卷 9, 期 5, 页码 -出版社
MDPI
DOI: 10.3390/jcm9051541
关键词
biomarker; circulating tumor nucleic acids; circulating tumor cells; extracellular vesicles; proteomics and metabolomics
资金
- Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) [410853455]
- Fundacao para a Ciencia e a Tecnologia, Portugal [PTDC/MED-PAT/31882/2017]
- la Caixa Foundation, Spain [LCF/PR/HP17/52190004]
- Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)
- Fundação para a Ciência e a Tecnologia [PTDC/MED-PAT/31882/2017] Funding Source: FCT
Hepatocellular carcinoma (HCC) represents the sixth most common cancer worldwide and the third most common cause of cancer-related death. One of the major problems faced by researchers and clinicians in this area is the lack of reliable disease biomarkers, which would allow for an earlier diagnosis, follow-up or prediction of treatment response, among others. In this regard, the HCC circulome, defined as the pool of circulating molecules in the bloodstream derived from the primary tumor, represents an appealing target, the so called liquid biopsy. Such molecules encompass circulating tumor proteins, circulating tumor cells (CTCs), extracellular vesicles (EVs), tumor-educated platelets (TEPs), and circulating tumor nucleic acids, namely circulating tumor DNA (ctDNA) and circulating tumor RNA (ctRNA). In this article, we summarize recent findings highlighting the promising role of liquid biopsies as novel potential biomarkers in HCC, emphasizing on its clinical performance.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据